Genetically engineered virulent phages to detect and control emergent pathogenic bacteria
Pherecydes Pharma is proud to announce the publication of it first scientifique paper in: Bioscurity and Bioterrorism: Biodefense Strategy, Practice and Science.
Launching of our Phage Industry Newsletter !
We are pleased to introduce our quarterly bulletin entitled The Phage Industry Newsletter.
Participation at the French Biotech Tour
French and American biotech companies met on March 15 and 17 2010 to see how they can collaborate to develop effective therapeutics and diagnostics to combat infectious diseases. MRSA and other bacterial threats have been a few of the hot topics.
8th ASM Biodefense & Emerging Diseases Conference
For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.
Perspectives
Nanotechnology and nanodevices
With the full control of T4 phage replication cycle and the possibility to introduce mutations and/or coding sequences as needed, without affecting the main phage functions, Pherecydes Pharma owns a biodevice with applications in nanotechnologies.
We are open to discuss potential collaborations for developing under contract or co-developing new nanodevices with applications in various fields.
With the full control of T4 phage replication cycle and the possibility to introduce mutations and/or coding sequences as needed, without affecting the main phage functions, Pherecydes Pharma owns a biodevice with applications in nanotechnologies.
We are open to discuss potential collaborations for developing under contract or co-developing new nanodevices with applications in various fields.
- Phage therapy biodrugs;
- Medical application diagnostic tools.
Création & hébergement : Infini'click